Searched for: subject%3A%22microfluidics%22
(1 - 6 of 6)
document
Neves Sao Pedro, M. (author), Isaksson, Madelène (author), Gomis-Fons, Joaquín (author), Eppink, Michel H.M. (author), Nilsson, Bernt (author), Ottens, M. (author)
The implementation of continuous processing in the biopharmaceutical industry is hindered by the scarcity of process analytical technologies (PAT). To monitor and control a continuous process, PAT tools will be crucial to measure real-time product quality attributes such as protein aggregation. Miniaturizing these analytical techniques can...
journal article 2023
document
Neves Sao Pedro, M. (author), Eppink, Michel H.M. (author), Ottens, M. (author)
The lack of process analytical technologies able to provide real-time information and process control over a biopharmaceutical process has long impaired the transition to continuous biomanufacturing. For the monoclonal antibody (mAb) production, aggregate formation is a major critical quality attribute (CQA) with several known process...
journal article 2023
document
Neves Sao Pedro, M. (author), Silva dos Santos, M. (author), Eppink, Michel H.M. (author), Ottens, M. (author)
A major challenge in the transition to continuous biomanufacturing is the lack of process analytical technology (PAT) tools which are able to collect real-time information on the process and elicit a response to facilitate control. One of the critical quality attributes (CQAs) of interest during monoclonal antibodies production is aggregate...
journal article 2022
document
Picanço Castanheira Da Silva, T. (author), Eppink, Michel (author), Ottens, M. (author)
Biopharmaceuticals are becoming increasingly important in modern healthcare. Monoclonal antibodies (mAb) are one of the most widely used therapeutic proteins and are important for the treatment of cancer and autoimmune diseases, among others. After cell culture there are still large amounts of other impurities (e.g. host cell proteins) in...
journal article 2022
document
Neves Sao Pedro, M. (author), Klijn, M.E. (author), Eppink, Michel H.M. (author), Ottens, M. (author)
The transition to continuous biomanufacturing is considered the next step to reduce costs and improve process robustness in the biopharmaceutical industry, while also improving productivity and product quality. The platform production process for monoclonal antibodies (mAbs) is eligible for continuous processing to lower manufacturing costs...
review 2021
document
Picanço Castanheira Da Silva, T. (author), Eppink, Michel (author), Ottens, M. (author)
Process development in the biotech industry leads to investments around hundred of millions of dollars. It is important to mitigate costs without neglecting the quality of process development. Biopharmaceutical process development is important for companies to develop new processes and be first to market, improve a pre-established process, or...
review 2021
Searched for: subject%3A%22microfluidics%22
(1 - 6 of 6)